Literature DB >> 28621554

Gut microbiota changes and chronic hepatitis C virus infection.

Tomislav Preveden1, Emidio Scarpellini2, Natasa Milić3, Francesco Luzza4, Ludovico Abenavoli1,4.   

Abstract

INTRODUCTION: Hepatitis C virus (HCV) infection is a global health problem with 150 million infected people worldwide. Liver can be greatly affected by changes in gut microbiota due to increased intestinal permeability with passage of microbial antigens into the liver through the portal circulation. The concept of 'gut-liver' axis is important to understand the pathophysiology of several liver diseases. Several recent studies also revealed that an altered gut microbiota can be implicated in the pathogenesis of HCV-induced chronic liver disease (CHC). Areas covered: An overview of intestinal microflora composition, host reaction during CHC, and a description of relevant clinical trials on the use of probiotics in this field. Expert commentary: HCV patients gut microbiota composition is stable over liver disease stages. This is a unique example of gut disbiosis stability vs. NAFLD, HBV, HIV, and HCV co-infected patients. The impact of HCV infection on intestinal permeability allows gut disbiosis starting, maintenance and its proinflammatory effect until liver cirrhosis and HCC development. HCV eradication has unraveled the strong impact of gut microbiota unbalance on liver disease development with possible future implications for probiotics use to change the natural history of cirrhosis progression.

Entities:  

Keywords:  Hepatitis C virus; gut; intestinal permeability; liver disease; microbiota; probiotics

Mesh:

Year:  2017        PMID: 28621554     DOI: 10.1080/17474124.2017.1343663

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  27 in total

1.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

2.  Different profiles of neurocognitive impairment in patients with hepatitis B and C virus infections.

Authors:  Chun-Hsiang Tan; Meng-Chia Chang; Wei-Fang Tsai; Wan-Long Chuang; Jee-Fu Huang; Zu-Yau Lin; Chia-Yen Dai; Ming-Lun Yeh; Chi-Ting Li; Rwei-Ling Yu
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

3.  Are probiotics effective in reversing non-alcoholic steatohepatitis?

Authors:  Ludovico Abenavoli; Luigi Boccuto; Emidio Scarpellini
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

Review 4.  Intestinal Microbiota-A Promising Target for Antiviral Therapy?

Authors:  Mengling Yang; Yang Yang; Qingnan He; Ping Zhu; Mengqi Liu; Jiahao Xu; Mingyi Zhao
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

5.  Exploring the Anal Microbiome in HIV Positive and High-Risk HIV Negative Women.

Authors:  Jessica Wells; Jinbing Bai; Despina Tsementzi; Camber Ileen Jhaney; Antonina Foster; Deborah Watkins Bruner; Theresa Gillespie; Yunxiao Li; Yi-Juan Hu
Journal:  AIDS Res Hum Retroviruses       Date:  2022-03       Impact factor: 2.205

Review 6.  Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2020-11-28       Impact factor: 33.883

7.  Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies.

Authors:  Jessica L Petrick; Andrea A Florio; Jill Koshiol; Ruth M Pfeiffer; Baiyu Yang; Kelly Yu; Chien-Jen Chen; Hwai-I Yang; Mei-Hsuan Lee; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2020-06-08       Impact factor: 7.316

8.  The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer.

Authors:  Nahum Méndez-Sánchez; Alejandro Valencia-Rodriguez; Alfonso Vera-Barajas; Ludovico Abenavoli; Emidio Scarpellini; Guadalupe Ponciano-Rodriguez; David Q-H Wang
Journal:  Hepatoma Res       Date:  2020-02-20

9.  Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.

Authors:  Ruipeng Zheng; Guoqiang Wang; Zhiqiang Pang; Nan Ran; Yinuo Gu; Xuewa Guan; Yuze Yuan; Xu Zuo; He Pan; Jingtong Zheng; Fang Wang
Journal:  Cancer Med       Date:  2020-04-12       Impact factor: 4.452

10.  Clinical impact of microbiome in patients with decompensated cirrhosis.

Authors:  Theodora Oikonomou; George V Papatheodoridis; Michael Samarkos; Ioannis Goulis; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2018-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.